← Back to Search

Device

TMS Targeting Methods for Depression (XRnav Trial)

N/A
Waitlist Available
Led By Jennifer A McNab, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 weeks
Awards & highlights

Summary

This trial is testing a special headset that combines real and virtual elements to help doctors place a magnetic coil on the head more accurately during TMS treatment for depression. The goal is to see if this method improves treatment outcomes compared to traditional methods. Transcranial magnetic stimulation (TMS) is a relatively new technique used to treat depression by delivering magnetic radiation to the head using a hand-held coil.

Who is the study for?
This trial is for adults aged 18-75 with treatment-resistant depression who are prescribed transcranial magnetic stimulation (TMS) therapy. They must be MRI-compatible, meaning no metal in the body and able to complete screening at specific centers. Excluded are those with neurological disorders, pacemakers or certain implants, and a history of substance abuse.
What is being tested?
The study tests if using mixed reality devices can improve TMS targeting for treating depression compared to traditional scalp measurements or commercial neuronavigation systems. It aims to see if this method reduces setup time and is practical in clinical settings.
What are the potential side effects?
While not explicitly stated here, common side effects of TMS may include headache, scalp discomfort at the site of stimulation, tingling or spasms of facial muscles.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with response to TMS

Trial Design

2Treatment groups
Active Control
Group I: No neuronavigationActive Control1 Intervention
For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.
Group II: Mixed reality neuronavigationActive Control2 Interventions
For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment for depression that uses magnetic fields to stimulate nerve cells in the brain, particularly the dorsolateral prefrontal cortex, which is often underactive in depression. This stimulation helps to normalize brain activity and improve mood. Understanding these mechanisms is crucial for depression patients as it emphasizes the importance of targeting specific brain regions to achieve therapeutic effects, potentially leading to more effective and personalized treatment options.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,448 Previous Clinical Trials
17,492,334 Total Patients Enrolled
108 Trials studying Depression
93,806 Patients Enrolled for Depression
Jennifer A McNab, PhDPrincipal InvestigatorStanford University

Media Library

Mixed reality neuronavigation (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04730180 — N/A
Depression Research Study Groups: No neuronavigation, Mixed reality neuronavigation
Depression Clinical Trial 2023: Mixed reality neuronavigation Highlights & Side Effects. Trial Name: NCT04730180 — N/A
Mixed reality neuronavigation (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04730180 — N/A
~40 spots leftby Jul 2026